Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3092Triple Negative Breast Neoplasms 504Ovarian Neoplasms 224Colorectal Neoplasms 189Carcinoma, Non-Small-Cell Lung 187Prostatic Neoplasms 180Neoplasms 171Lung Neoplasms 164Neoplasm Metastasis 159Melanoma 116Stomach Neoplasms 113Pancreatic Neoplasms 111Endometrial Neoplasms 105Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 87Head and Neck Neoplasms 81Colonic Neoplasms 81Carcinoma, Intraductal, Noninfiltrating 80Sarcoma 63Breast Carcinoma In Situ 61Carcinoma, Renal Cell 60Urinary Bladder Neoplasms 59Esophageal Neoplasms 58Motor Activity 57Brain Neoplasms 50Lymphedema 42Breast Cancer Female 40Advanced Breast Cancer 40Liver Neoplasms 39Gastrointestinal Neoplasms 38

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inoperable Locally Advanced HER2-Negative Breast Cancer × Breast × 1 year × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡